Several haematological malignancies, including multiple myeloma (MM) and acute myeloid
leukaemia (AML), have well-defined precursor states that precede the development of overt …

Although survival of multiple myeloma patients has at least doubled during recent years,
most patients eventually relapse, and treatment at this stage may be particularly complex. At …

Tumor immunometabolism contributes substantially to tumor proliferation and immune cell
activity, and thus plays a crucial role in the efficacy of cancer immunotherapy. Modulation of …

The main obstacle of multiple myeloma (MM) therapy is the compromised immune
microenvironment, which leads to MM relapses and extramedullary disease progression. In …

Abstract Purpose: PD-1/PD-L1 signaling promotes tumor growth while inhibiting effector cell–
mediated antitumor immune responses. Here, we assessed the impact of single and dual …

Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma that is
associated with a poor outcome. Currently, the treatment needs of NKTCL remain unmet …

The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of
adults with cancer has never been performed in a prospective patient cohort. We evaluated …

The checkpoint blockade‐based immunotherapy has recently emerged as a promising
approach for tumor treatment, but its clinical implementation has been impeded by poor …

Abstract Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune
evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody …

Despite the advent of bortezomib, thalidomide and lenalidomide, relapse of multiple
myeloma (MM) is common, and novel therapies are needed urgently. 1 Interactions of MM …